TrialsgrambetaRCTs are beautiful

A-HeFT

2004

African-American Heart Failure Trial

In 1,050 Black patients with NYHA III-IV HFrEF on standard therapy, fixed-dose isosorbide dinitrate plus hydralazine improved a composite of survival, HF hospitalisation and quality of life compared with placebo.

Result

Efficacy: Weighted composite score (all-cause death, first HF hospitalisation, change in quality of life)HR 0.57 · P = 0.01

Below 1 favours fixed-dose isosorbide dinitrate plus hydralazine, above 1 favours placebo.

Event rates
Absolute difference
4.0 points
NNT
26

Absolute difference and NNT are derived from the event rates.

Also reported: Composite score significantly favoured active therapy; trial halted early for mortality benefit and fewer first HF hospitalisations (16.4% vs 22.4%).

Original publication
Subtopic
hydralazine/nitrate
Design
Double-blind placebo-controlled RCT, stopped early for benefit
Relevance
Supporting: context rather than must-know.
Source
Taylor AL, et al. N Engl J Med. 2004;351(20):2049-2057.doi 10.1056/NEJMoa042934

Discussion & critique

Enrolled only self-identified Black patients already on ACEi/beta-blockers, limiting generalisability and raising questions about race-based prescribing. Established fixed-dose isosorbide dinitrate/hydralazine as add-on therapy.

Discussed in podcasts